Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3 patients cohort with treatment indication with interferon α 2b and ribavirin for 24 weeks, and the verification of sustained virological response at week 48. The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health: http://portal.saude.gov.br/portal/arquivos/pdf/pcdt\_hepatite\_c\_2011\_retificado.pdf
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
85
1. interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks 2. ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks
Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital Universitário Clementino Fraga Filho (Clementino Fraga Filho University Hospital)
Rio de Janeiro, Rio de Janeiro, Brazil
Adverse events
* Diary for recording adverse events by patients daily; * Monthly follow-up interview with MD and PharmD
Time frame: Up to 24 weeks
Sustained virological response
Time frame: 24 weeks after finishing treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.